Adagene Management

Management criteria checks 2/4

Adagene's CEO is Peizhi Luo, appointed in Nov 2011, has a tenure of 14.58 years. directly owns 0.18% of the company’s shares, worth €368.38K. The average tenure of the management team and the board of directors is 7.7 years and 4.6 years respectively.

Key information

Peizhi Luo

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	14.6yrs
CEO ownership	0.2%
Management average tenure	7.7yrs
Board average tenure	4.6yrs

Recent management updates

Recent updates

CEO

Peizhi Luo (60 yo)

14.6yrs

Tenure

Dr. Dr. Peter P. Luo (Peizhi), Ph D., also known as Peizhi, is Founder & Chief Executive Officer and Director of Adagene (Suzhou) Limited. and serves as its Chief Executive Officer since November 2011 and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Peter P. Luo	Co- Founder	14.6yrs	no data	0.18% € 368.4k
Man Kin Tam	CFO & Director	6.8yrs	no data	0.14% € 287.3k
Ling Zhou	Executive Director & Head of Human Resources	6.7yrs	no data	0.0036% € 7.3k
Qinghai Zhao	Chief Manufacturing Officer	5.7yrs	no data	0.16% € 320.8k
Mickael Chane-Du	Chief Strategy Officer	1.4yrs	no data	0.34% € 688.7k
Chunfang Gu	Executive Director of Finance	no data	no data	0.0085% € 17.4k
Yan Li	Senior Vice President of Bioinformatics & Information Technology	14.6yrs	no data	no data
Xiaohong She	Senior VP & Head of Clinical Operations	14.6yrs	no data	0.068% € 138.0k
Guizhong Liu	Senior Vice President of Early Drug Discovery	10.7yrs	no data	no data
Alexander Goergen	VP & Head of Business Development	8.7yrs	no data	no data
Jiping Zha	Executive Vice President of Clinical Development	4.8yrs	no data	no data
Songmao Zheng	Senior VP of Clinical Pharmacology & Quantitative Sciences	no data	no data	no data

7.7yrs

Average Tenure

55yo

Average Age

Experienced Management: 978's management team is seasoned and experienced (7.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Peter P. Luo	Co- Founder	8.3yrs	no data	0.18% € 368.4k
Man Kin Tam	CFO & Director	5.3yrs	no data	0.14% € 287.3k
Li Zhu	Independent Director	2.8yrs	no data	no data
Steven Alan Fischkoff	Member of Scientific & Strategic Advisory Board	4.8yrs	no data	no data
Robert Jay Spiegel	Member Scientific and Strategic Advisory Board	4.8yrs	no data	no data
Cuong Viet Do	Independent Director	3.6yrs	no data	no data
Ulf Grawunder	Independent Director	2.3yrs	no data	no data
David R. Gandara	Member Scientific & Strategic Advisory Board	4.4yrs	no data	no data
Heinz-Josef Lenz	Member of Scientific & Strategic Advisory Board	2.3yrs	no data	no data
Aurelien Marabelle	Member of Scientific & Strategic Advisory Board	3.3yrs	no data	no data
Yiu Leung Cheung	Independent Director	5.3yrs	no data	no data
Stanley Frankel	Member Scientific & Strategic Advisory Board	4.8yrs	no data	no data

4.6yrs

Average Tenure

66yo

Average Age

Experienced Board: 978's board of directors are considered experienced (4.6 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/15 22:00
End of Day Share Price	2026/06/15 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Adagene Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ziyi Chen	Goldman Sachs
Paul Jeng	Guggenheim Securities, LLC
Yu He	H.C. Wainwright & Co.

Adagene Management

Management criteria checks 2/4

Key information

Recent management updates

Adagene Inc. Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Adagene Inc. Announces Board Changes

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Adagene Inc. Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Adagene Inc. has completed a Follow-on Equity Offering in the amount of $69.9975 million.

Adagene Inc. has filed a Follow-on Equity Offering.

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Adagene Inc. Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA®? (Pembrolizumab) in Microsatellite Stable Colorectal Cancer

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA

Adagene Inc. announced that it expects to receive $25 million in funding from Sanofi Foreign Participations B.V.

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA®? (Pembrolizumab) in Colorectal Cancer At the American Society of Clinical Oncology Annual Meeting

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

Adagene Inc. Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

New minor risk - Market cap size

New minor risk - Market cap size

New minor risk - Market cap size

First half 2024 earnings released: US$0.39 loss per share (vs US$0.094 loss in 1H 2023)

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$1.83 loss per share (vs US$1.85 loss in FY 2022)

Adagene Inc. Announces Board Changes

New minor risk - Financial data availability

Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board

New major risk - Revenue and earnings growth

Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody

Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium

Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126

First half 2023 earnings released: US$0.094 loss per share (vs US$1.09 loss in 1H 2022)

Full year 2022 earnings released: US$1.85 loss per share (vs US$1.83 loss in FY 2021)

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial

Adagene Inc. Appoints Cuong Do to Board of Directors and Audit Committee

High number of new and inexperienced directors

Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors

Adagene Inc. Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors

First half 2022 earnings released: US$1.09 loss per share (vs US$1.02 loss in 1H 2021)

High number of new and inexperienced directors

Adagene Inc. (NasdaqGM:ADAG) announces an Equity Buyback for $10 million worth of its shares.

Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels

Adagene Inc. Presents Data Demonstrating First and Best-In-Class Potential for Differentiated Preclinical Antibody Candidates At American Association for Cancer Research (Aacr) Annual Meeting 2022

High number of new and inexperienced directors

Adagene Inc. Announces Board and Management Changes

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116

Adagene Inc. Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1B/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore

Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab

Director Yu Miao has left the company

Adagene Inc. Announces Clinical Data from its ADG106 NEObodyTM Program

Adagene Inc. Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126 for the Treatment of Various Advanced Solid Tumors

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources